Savara Secures Key Patents for MOLBREEVI in Europe and Australia
Event summary
- Savara Inc. has secured patents for the liquid formulation of MOLBREEVI in Europe and Australia, valid until March 2041.
- European patent No.4121000 and Australian patent No.62/990,810 cover the liquid formulation of MOLBREEVI.
- MOLBREEVI is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) for autoimmune pulmonary alveolar proteinosis (PAP).
- Savara is advancing equivalent patent filings in the U.S., including a patent for the drug-device combination.
The big picture
Savara's patent wins strengthen its intellectual property portfolio for MOLBREEVI, a critical asset in the rare respiratory disease space. The company is positioning itself as a leader in treating autoimmune PAP, a niche market with high unmet medical needs. These patents provide long-term protection and could attract potential partners or investors looking to capitalize on Savara's proprietary technology.
What we're watching
- Patent Strategy
- How Savara's patent filings in the U.S. will impact its market position and competitive advantage.
- Regulatory Progress
- The pace at which MOLBREEVI advances through Phase 3 development and regulatory approvals.
- Market Expansion
- Whether Savara can leverage these patents to secure commercial partnerships in Europe and Australia.